The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis

Medical Decision Making

Volumn 37, Issue 8, 2017, Pages 894-904

  Cameron, Chris ^a   Ewara, Emmanuel ^b   Wilson, Florence R ^a   Varu, Abhishek ^a   Dyrda, Peter ^b   Hutton, Brian ^c,d   Ingham, Michael ^e  

^a Department of Data Analytics and Evidence Synthesis   (Canada)

^b Janssen Inc   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Janssen Scientific Affairs LLC   (United States)

Author keywords

biologics; network meta analysis; ulcerative colitis

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT; PLACEBO; TUMOR NECROSIS FACTOR;

ANTAGONISTS AND INHIBITORS; BAYES THEOREM; HUMAN; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; BAYES THEOREM; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; HUMANS; META-ANALYSIS AS TOPIC; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85030713046     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X17711933     Document Type: Article

References (19)

1. Caldwell DM, Ades AE, Higgins JPT,. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331: 897-900.
2. Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014; 39: 660-71.
3. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ,. Ulcerative colitis. Lancet. 2012; 380: 1606-19.
4. Danese S, Fiorino G, Peyrin-biroulet L, Lucenteforte E, Virgili G,. Biological agents for moderately to severely active ulcerative colitis. Ann Intern Med. 2014; 160: 704-11.
5. Thorlund K, Druyts E, Toor K, Mills EJ,. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015; 9: 693-700.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005: 2462-76.
7. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60: 780-7.
8. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142: 257-265.e3.
9. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 96-109.e1.
10. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014; 146: 85-95.
11. Thorlund K, Druyts E, Toor K, Jansen JP, Mills EJ,. Incorporating alternative design clinical trials in network meta-analyses. Clin Epidemiol. 2015: 29-35.
12. Lunn DJ, Thomas A, Best N, Spiegelhalter D,. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000; 10: 325-37.
13. Dias S, Sutton AJ, Ades a E, Welton NJ,. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013; 33: 607-17.
14. Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open. 2014; 4: e004301.
15. Salanti G, Ades A, Ioannidis J,. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011; 64: 163-71.
16. FDA. Adaptive Design Clinical Trials for Drugs and Biologics. 2010. Available from: URL: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm201790.pdf.
17. Hatfield I, Allison A, Flight L, Julious SA, Dimairo M,. Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials. 2016; 17: 150.
18. Sutton a J, Abrams KR,. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001; 10: 277-303.
19. Briggs A, Claxton K, Sculpher M,. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.